Terumo Kabushiki Kaisha

Roche Molecular Systems, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Shigeru Tamatsukuri

Koji Nakamura

Yoshihiko Abe

Masaaki Oka

Yoshihiko Hamamoto

Takeshi Akiyama

Tetsuya Oyauchi

Yusuke Nozaki

Shigeru Suzuki

Hideaki Kiminami

Ayumi Kumagai

Norio Iizuka

Nozomi Ami

Toshiaki Miura

Toyoki Moribe

A medical container for accommodating a protein solution formulation, in which the medical container is formed from a cycloolefin polymer, sterilized with high-pressure steam, and suppresses oxidization of amino acid residues in a protein in a protein solution formulation accommodated in the medical container.

Medical container for accommodating protein solution formulation

A myocardial infarction detection method and apparatus is described that includes a stiffness measurement step of measuring myocardial stiffness of a cardiac muscle of a subject, and a determination step of determining, based on the myocardial stiffness, whether or not infarction is present in the cardiac muscle.

Myocardial infarction detection method, apparatus, and medical device

A method for assessing pain caused by administration of a drug solution includes: anesthetizing an experimental animal; inserting a measurement electrode into skeletal muscle of the anesthetized experimental animal; puncturing an injection needle into a predetermined part of the anesthetized experimental animal while measuring a myoelectric potential of the skeletal muscle with the measurement electrode; administering a drug solution to the anesthetized experimental animal; and (i) measuring a duration time of the myoelectric response caused by the administration of the drug solution, and/or (ii) measuring an EMG intensity obtained by integrating absolute values of myoelectric potentials during a period from occurrence of the myoelectric response by the administration of the drug solution to disappearance of the myoelectric response.

Method for assessing pain caused by administration of drug solution, and method for selecting drug solution administration

A syringe is disclosed, which includes a needle having an outer cylinder including an outer cylinder body part and a needle fixing part provided at a distal end part of the outer cylinder body part; an injection needlehaving a puncturing needle tip at a distal end and fixed to the needle fixing part; and a gasket housed in the outer cylinder. The injection needle is such a tapered part holding injection needle that a puncturing time piercing part having a needle tip has an outer diameter of 0.42 mm or less and has a thickness of 0.1 mm or less, or the injection needle is such a small diameter thin injection needle as to have a thickness of 0.04 mm or less. The gasket includes a gasket body and a soft coating provided on a portion that comes into contact with the inner surface of the outer cylinder.

Syringe with needle, prefilled syringe, and medical liquid administration tool using the same

The present invention provides a novel method for detection of liver cancer. This method detects high-sensitively, high-specifically, simply and accurately liver cancer, especially that in early stage by identifying and/or quantifying methylation on particular genes and/or their DNA fragments in clinical specimens, and by combining said methylated DNA values with existing tumor marker values and/or DNA amounts in blood. This invention also detects a precancerous lesion, detects a risk of recurrence after treatment of liver cancer, detects malignancy of liver cancer and monitors progression of liver cancer with time by the same method. As for particular genes, BASP1 gene, SPINT2 gene, APC gene, CCND2 gene, CFTR gene, RASSF1 gene and SRD5A2 gene are mentioned.

Liver cancer methods and compositions

Growing community of inventors

Tokyo, Japan

Shigeru Tamatsukuri